Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
2
×
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
clinical trials
duchenne muscular dystrophy
dyne therapeutics
eli lilly
europe blog main
europe top stories
facioscapulohumeral muscular dystrophy
gastrointestinal stromal tumors
gene therapy
genentech
indiana blog main
indiana top stories
joshua brumm
kaleido biosciences
life science
medullary thyroid cancer
muscular dystrophy
myotonic dystrophy type 1
new york blog main
non-small cell lung cancer
novartis
pralsetinib
What
drug
2
×
genetic
2
×
medicines
address
ago
approval
approves
biotechs
blueprint
cancer
carries
certain
considering
data
designed
diseases
dyne
early
expected
experimental
eyes
fda
having
humans
ipo
ipos
latest
long
muscle
pass
rare
reach
ret
signature
signatures
targeted
targeting
therapeutics
therapy
worked
Language
unset
2
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
genetic
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases